元力股份(300174.SZ):已於7月推出“事業合夥人中長期持股計劃”
格隆匯11月30日丨元力股份(300174.SZ)近期在接待機構投資者調研時表示,公司已於7月推出“事業合夥人中長期持股計劃”,2024年起開始,為期10年,每年度一期:通過賦予與公司有共同價值觀,願意與公司共創、共擔和共享的同事持股的長期激勵機制,有效激勵高級管理及核心技術人才的創業拼搏精神,有效推動與促進公司“經理人”向“合夥人”身份的轉變;將核心人才與公司深度綁定,保證人才隊伍的穩定性,促進公司長期健康發展,實現員工、公司和股東利益的多贏。具體實施方案將在每一年年度報吿披露後適時制定並實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.